Elicio Therapeutics Inc
ELTX9.940USD
-0.040-0.40%
交易中 （美東）報價延遲15分鐘
158.73M總市值
虧損本益比TTM
關於 Elicio Therapeutics Inc 公司
Elicio Therapeutics, Inc. 是一家臨牀階段的生物技術公司。該公司致力於開發用於治療癌症的免疫療法。該公司提供了一個平臺，即兩親物 (AMP)，可將免疫療法直接輸送到免疫系統的淋巴結（大腦中心）。該公司的主要候選產品 ELI-002 正在開發中，用於治療由 kirsten 大鼠肉瘤 (KRAS) 引起的癌症。該公司正在進行 ELI-002 (AMPLIFY-201) 的 I/II 期臨牀試驗。其 ELI-007 正在臨牀前研究中接受評估，用於治療突變型 v-raf 鼠肉瘤病毒致癌基因同源物 B1 (BRAF) 引起的癌症，而 ELI-008 正在臨牀前研究中接受評估，用於治療表達突變腫瘤蛋白 p53 (TP53) 的癌症。其AMP平臺在治療或預防癌症、傳染病等疾病方面具有廣闊的潛在應用前景。
公司簡介
公司代碼ELTX
公司名稱Elicio Therapeutics Inc
上市日期Feb 05, 2021
CEOMr. Robert (Bob) Connelly
員工數量32
證券類型Ordinary Share
年結日Feb 05
公司地址451 D Street, 5Th Floor
城市BOSTON
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編02459
電話18572090050
網址https://elicio.com/
公司代碼ELTX
上市日期Feb 05, 2021
CEOMr. Robert (Bob) Connelly
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
-5.71%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
12.72K
--
Ms. Karen J. Wilson
Ms. Karen J. Wilson
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
381.00
--
Dr. Julian Adams, Ph.D.
Dr. Julian Adams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Executive Vice President, Head - Research and Development, Chief Medical Officer
Executive Vice President, Head - Research and Development, Chief Medical Officer
--
--
Ms. Carol Ashe
Ms. Carol Ashe
Independent Director
Independent Director
--
--
Dr. Allen R. Nissenson, M.D.
Dr. Allen R. Nissenson, M.D.
Independent Director
Independent Director
--
--
Dr. Robert R. Ruffolo, Jr.
Dr. Robert R. Ruffolo, Jr.
Independent Director
Independent Director
--
--
Mr. Robert (Bob) Connelly
Mr. Robert (Bob) Connelly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
-5.71%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
12.72K
--
Ms. Karen J. Wilson
Ms. Karen J. Wilson
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
381.00
--
Dr. Julian Adams, Ph.D.
Dr. Julian Adams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Executive Vice President, Head - Research and Development, Chief Medical Officer
Executive Vice President, Head - Research and Development, Chief Medical Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月1日 週五
更新時間: 8月1日 週五
持股股東
股東類型
持股股東
持股股東
佔比
GKCC, LLC
33.86%
Actyus Private Equity SGIIC, S.A.
5.35%
Knoll Capital Management, LLC
3.94%
Clal Biotechnology Industries Ltd
3.01%
The Vanguard Group, Inc.
2.01%
Other
51.82%
持股股東
持股股東
佔比
GKCC, LLC
33.86%
Actyus Private Equity SGIIC, S.A.
5.35%
Knoll Capital Management, LLC
3.94%
Clal Biotechnology Industries Ltd
3.01%
The Vanguard Group, Inc.
2.01%
Other
51.82%
股東類型
持股股東
佔比
Corporation
39.21%
Hedge Fund
5.54%
Investment Advisor/Hedge Fund
3.32%
Holding Company
3.01%
Individual Investor
1.65%
Investment Advisor
0.97%
Research Firm
0.33%
Bank and Trust
0.11%
Other
45.86%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
59
8.71M
54.45%
+612.65K
2025Q1
71
8.88M
57.84%
+3.95M
2024Q4
66
3.95M
32.81%
+187.04K
2024Q3
70
4.16M
40.61%
+80.64K
2024Q2
82
4.28M
44.94%
+434.22K
2024Q1
108
4.00M
44.25%
+126.75K
2023Q4
114
4.22M
52.86%
+1.57M
2023Q3
132
2.88M
52.57%
+376.65K
2023Q2
138
2.82M
63.05%
+1.05M
2023Q1
137
1.45M
48.19%
-243.12K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
GKCC, LLC
5.42M
33.86%
--
--
Jun 03, 2025
Actyus Private Equity SGIIC, S.A.
856.38K
5.35%
+268.56K
+45.69%
Mar 31, 2025
Knoll Capital Management, LLC
630.91K
3.94%
--
--
Mar 31, 2025
Clal Biotechnology Industries Ltd
481.73K
3.01%
-52.31K
-9.80%
Apr 09, 2024
The Vanguard Group, Inc.
321.69K
2.01%
+75.87K
+30.86%
Mar 31, 2025
Hudson Bay Capital Management LP
182.73K
1.14%
+182.73K
--
Mar 31, 2025
Venkatesan (Jay R)
170.22K
1.06%
-10.31K
-5.71%
Mar 24, 2025
Geode Capital Management, L.L.C.
77.47K
0.48%
+6.75K
+9.54%
Mar 31, 2025
CM Management, LLC
55.00K
0.34%
+15.00K
+37.50%
Mar 31, 2025
Millennium Management LLC
52.22K
0.33%
+52.22K
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.02%
iShares Micro-Cap ETF
佔比0.02%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Jun 01, 2023
Merger
10<1
Jun 01, 2023
Merger
10<1
Jun 01, 2023
Merger
10<1
Jun 01, 2023
Merger
10<1
公告日期
類型
比率
Jun 01, 2023
Merger
10<1
Jun 01, 2023
Merger
10<1
Jun 01, 2023
Merger
10<1
Jun 01, 2023
Merger
10<1
